Industry Research Reports

Home > Reports > Pharma & Healthcare > 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Pharma & Healthcare

Published: 2024-01-13

Pages: 99 Pages

Report ld: 2630423

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

The global market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by region & country, by Type, and by Application.

The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13).

Market Segmentation

Report Metric
Details
Report Title
13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Companies Covered
Pfizer, Minhai Bio, Kexing Bio, Cansino Bio, Lanzhou Biological Preparations Institute
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market, Segment by Type
Serotype 6B

7F Serotype

Serotype 9V

14 Serotype

Serotype 18C

Serotype 19A

19F Serotype

23F Serotype

24F Serotype

Other
Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market, Segment by Application
Infants from 6 Weeks to 15 Months Old

Children Aged 15 Months to 5 Years
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Sales, revenue of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Sales, revenue of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Introduction
    1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Size Forecast
        1.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (2019-2030)
        1.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume (2019-2030)
        1.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Price (2019-2030)
    1.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Trends & Drivers
        1.3.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industry Trends
        1.3.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers & Opportunity
        1.3.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
        1.3.4 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players Revenue Ranking (2023)
    2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Company (2019-2024)
    2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players Sales Volume Ranking (2023)
    2.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Company Players (2019-2024)
    2.5 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Company (2019-2024)
    2.6 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base Distribution and Headquarters
    2.7 Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offered
    2.8 Key Manufacturers Time to Begin Mass Production of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
    2.9 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Competitive Analysis
        2.9.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Concentration Rate (2019-2024)
        2.9.2 Global 5 and 10 Largest Manufacturers by 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue in 2023
        2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) as of 2023)
    2.10 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Serotype 6B
        3.1.2 7F Serotype
        3.1.3 Serotype 9V
        3.1.4 14 Serotype
        3.1.5 Serotype 18C
        3.1.6 Serotype 19A
        3.1.7 19F Serotype
        3.1.8 23F Serotype
        3.1.9 24F Serotype
        3.1.10 Other
    3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type
        3.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, by Type (2019-2030)
        3.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, by Type (%) (2019-2030)
    3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Type
        3.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Type (2019 VS 2023 VS 2030)
        3.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume, by Type (2019-2030)
        3.3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume, by Type (%) (2019-2030)
    3.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Type (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Infants from 6 Weeks to 15 Months Old
        4.1.2 Children Aged 15 Months to 5 Years
    4.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application
        4.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, by Application (2019-2030)
        4.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, by Application (%) (2019-2030)
    4.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Application
        4.3.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Application (2019 VS 2023 VS 2030)
        4.3.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume, by Application (2019-2030)
        4.3.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume, by Application (%) (2019-2030)
    4.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Application (2019-2030)

 5 Segmentation by Region
    5.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region
        5.1.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region (2019-2024)
        5.1.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region (2025-2030)
        5.1.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region (%), (2019-2030)
    5.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region
        5.2.1 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region: 2019 VS 2023 VS 2030
        5.2.2 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (2019-2024)
        5.2.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (2025-2030)
        5.2.4 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (%), (2019-2030)
    5.3 Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Region (2019-2030)
    5.4 North America
        5.4.1 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        5.4.2 North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    5.5 Europe
        5.5.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        5.5.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    5.6 Asia Pacific
        5.6.1 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        5.6.2 Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    5.7 South America
        5.7.1 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        5.7.2 South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    5.8 Middle East & Africa
        5.8.1 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        5.8.2 Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value
        6.2.1 Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.2.2 Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume, 2019-2030
    6.3 United States
        6.3.1 United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.3.2 United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.4.2 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.5.2 China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
        6.5.3 China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.6.2 Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.7.2 South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.8.2 Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019-2030
        6.9.2 India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
        6.9.3 India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Pfizer
        7.1.1 Pfizer Company Information
        7.1.2 Pfizer Introduction and Business Overview
        7.1.3 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2019-2024)
        7.1.4 Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
        7.1.5 Pfizer Recent Development
    7.2 Minhai Bio
        7.2.1 Minhai Bio Company Information
        7.2.2 Minhai Bio Introduction and Business Overview
        7.2.3 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2019-2024)
        7.2.4 Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
        7.2.5 Minhai Bio Recent Development
    7.3 Kexing Bio
        7.3.1 Kexing Bio Company Information
        7.3.2 Kexing Bio Introduction and Business Overview
        7.3.3 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2019-2024)
        7.3.4 Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
        7.3.5 Kexing Bio Recent Development
    7.4 Cansino Bio
        7.4.1 Cansino Bio Company Information
        7.4.2 Cansino Bio Introduction and Business Overview
        7.4.3 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2019-2024)
        7.4.4 Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
        7.4.5 Cansino Bio Recent Development
    7.5 Lanzhou Biological Preparations Institute
        7.5.1 Lanzhou Biological Preparations Institute Company Information
        7.5.2 Lanzhou Biological Preparations Institute Introduction and Business Overview
        7.5.3 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales, Revenue and Gross Margin (2019-2024)
        7.5.4 Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
        7.5.5 Lanzhou Biological Preparations Institute Recent Development

 8 Industry Chain Analysis
    8.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industrial Chain
    8.2 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Model
        8.5.2 Sales Channel
        8.5.3 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Trends
    Table 2. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Drivers & Opportunity
    Table 3. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Challenges
    Table 4. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Restraints
    Table 5. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue Market Share by Company (2019-2024)
    Table 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Company (2019-2024) & (K Units)
    Table 8. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Company (2019-2024) & (US$/Unit)
    Table 10. Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13)
    Table 13. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Type: 2019 VS 2023 VS 2030 (K Units)
    Table 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Type (2019-2024) & (K Units)
    Table 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Type (2025-2030) & (K Units)
    Table 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2019-2024) & (US$/Unit)
    Table 27. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2025-2030) & (US$/Unit)
    Table 28. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Application: 2019 VS 2023 VS 2030 (K Units)
    Table 34. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Application (2019-2024) & (K Units)
    Table 35. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Application (2025-2030) & (K Units)
    Table 36. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2019-2024) & (US$/Unit)
    Table 39. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2025-2030) & (US$/Unit)
    Table 40. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region (2019-2024) & (%)
    Table 44. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Region (2025-2030) & (%)
    Table 45. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (K Units): 2019 VS 2023 VS 2030
    Table 46. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (2019-2024) & (K Units)
    Table 47. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (2025-2030) & (K Units)
    Table 48. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (2019-2024) & (%)
    Table 49. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Region (2025-2030) & (%)
    Table 50. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Region (2019-2024) & (US$/Unit)
    Table 51. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Average Price by Region (2025-2030) & (US$/Unit)
    Table 52. Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume, (2019-2024) & (K Units)
    Table 56. Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume, (2025-2030) & (K Units)
    Table 57. Pfizer Company Information
    Table 58. Pfizer Introduction and Business Overview
    Table 59. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 60. Pfizer 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
    Table 61. Pfizer Recent Development
    Table 62. Minhai Bio Company Information
    Table 63. Minhai Bio Introduction and Business Overview
    Table 64. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 65. Minhai Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
    Table 66. Minhai Bio Recent Development
    Table 67. Kexing Bio Company Information
    Table 68. Kexing Bio Introduction and Business Overview
    Table 69. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 70. Kexing Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
    Table 71. Kexing Bio Recent Development
    Table 72. Cansino Bio Company Information
    Table 73. Cansino Bio Introduction and Business Overview
    Table 74. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 75. Cansino Bio 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
    Table 76. Cansino Bio Recent Development
    Table 77. Lanzhou Biological Preparations Institute Company Information
    Table 78. Lanzhou Biological Preparations Institute Introduction and Business Overview
    Table 79. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)
    Table 80. Lanzhou Biological Preparations Institute 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Offerings
    Table 81. Lanzhou Biological Preparations Institute Recent Development
    Table 82. Key Raw Materials Lists
    Table 83. Raw Materials Key Suppliers Lists
    Table 84. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Downstream Customers
    Table 85. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Distributors List
    Table 86. Research Programs/Design for This Report
    Table 87. Key Data Information from Secondary Sources
    Table 88. Key Data Information from Primary Sources
List of Figures
    Figure 1. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Product Picture
    Figure 2. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume (2019-2030) & (K Units)
    Figure 5. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Price (2019-2030) & (US$/Unit)
    Figure 6. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Report Years Considered
    Figure 7. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Players Sales Volume Ranking (2023) & (K Units)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Revenue in 2023
    Figure 10. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Serotype 6B Picture
    Figure 12. 7F Serotype Picture
    Figure 13. Serotype 9V Picture
    Figure 14. 14 Serotype Picture
    Figure 15. Serotype 18C Picture
    Figure 16. Serotype 19A Picture
    Figure 17. 19F Serotype Picture
    Figure 18. 23F Serotype Picture
    Figure 19. 24F Serotype Picture
    Figure 20. Other Picture
    Figure 21. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 22. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value Market Share by Type, 2023 & 2030
    Figure 23. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Type (2019 VS 2023 VS 2030) & (K Units)
    Figure 24. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume Market Share by Type, 2023 & 2030
    Figure 25. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Type (2019-2030) & (US$/Unit)
    Figure 26. Product Picture of Infants from 6 Weeks to 15 Months Old
    Figure 27. Product Picture of Children Aged 15 Months to 5 Years
    Figure 28. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 29. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value Market Share by Application, 2023 & 2030
    Figure 30. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume by Application (2019 VS 2023 VS 2030) & (K Units)
    Figure 31. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume Market Share by Application, 2023 & 2030
    Figure 32. Global 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Price by Application (2019-2030) & (US$/Unit)
    Figure 33. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (2019-2030) & (US$ Million)
    Figure 34. North America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    Figure 35. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (2019-2030) & (US$ Million)
    Figure 36. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    Figure 37. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (2019-2030) & (US$ Million)
    Figure 38. Asia Pacific 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    Figure 39. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (2019-2030) & (US$ Million)
    Figure 40. South America 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    Figure 41. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (2019-2030) & (US$ Million)
    Figure 42. Middle East & Africa 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Country (%), 2023 VS 2030
    Figure 43. Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value (%), (2019-2030)
    Figure 44. Key Countries/Regions 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Volume (%), (2019-2030)
    Figure 45. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2030) & (US$ Million)
    Figure 46. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
    Figure 47. United States 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (%), 2023 VS 2030
    Figure 48. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2030) & (US$ Million)
    Figure 49. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
    Figure 50. Europe 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (%), 2023 VS 2030
    Figure 51. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2030) & (US$ Million)
    Figure 52. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
    Figure 53. China 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (%), 2023 VS 2030
    Figure 54. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2030) & (US$ Million)
    Figure 55. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
    Figure 56. Japan 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (%), 2023 VS 2030
    Figure 57. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2030) & (US$ Million)
    Figure 58. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
    Figure 59. South Korea 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (%), 2023 VS 2030
    Figure 60. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2030) & (US$ Million)
    Figure 61. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
    Figure 62. Southeast Asia 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (%), 2023 VS 2030
    Figure 63. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value, (2019-2030) & (US$ Million)
    Figure 64. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Type (%), 2023 VS 2030
    Figure 65. India 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Sales Value by Application (%), 2023 VS 2030
    Figure 66. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Industrial Chain
    Figure 67. 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) Manufacturing Cost Structure
    Figure 68. Channels of Distribution (Direct Sales, and Distribution)
    Figure 69. Bottom-up and Top-down Approaches for This Report
    Figure 70. Data Triangulation
    Figure 71. Key Executives Interviewed

Description

The global market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope
This report aims to provide a comprehensive presentation of the global market for 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) by region & country, by Type, and by Application.

The 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13).

Market Segmentation